{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T18:58:17Z","timestamp":1781895497964,"version":"3.54.5"},"reference-count":38,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Standard treatment regimens for the management of patients with refractory splenic marginal zone lymphoma (SMZL) are currently unavailable. Here, we report a case of SMZL, which, after failing multiple therapeutics, demonstrated an impressive clinical response to combined Venetoclax and Velcade (V2), a treatment combination currently being investigated in the setting of refractory multiple myeloma. We also report a unique histopathology and mutational profile that may have important implications for the characterization and prognosis of SMZL.<\/jats:p>","DOI":"10.3390\/curroncol29060328","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T10:08:24Z","timestamp":1654510104000},"page":"4117-4124","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bortezomib (Velcade) (V2) Therapy"],"prefix":"10.3390","volume":"29","author":[{"given":"Kyle C.","family":"Roche","sequence":"first","affiliation":[{"name":"Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC 20037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"DeRosa","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Maryland Medical Center, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Ling","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pathology, George Washington University School of Medicine and Health Sciences, Washington, DC 20037, USA"},{"name":"Department of Pathology, Veterans Health Administration Medical Center, Washington, DC 20422, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1438-9665","authenticated-orcid":false,"given":"Victor E.","family":"Nava","sequence":"additional","affiliation":[{"name":"Department of Pathology, George Washington University School of Medicine and Health Sciences, Washington, DC 20037, USA"},{"name":"Department of Pathology, Veterans Health Administration Medical Center, Washington, DC 20422, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC 20037, USA"},{"name":"Department of Pathology, Veterans Health Administration Medical Center, Washington, DC 20422, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.bjhh.2016.09.014","article-title":"Splenic marginal zone lymphoma: A literature review of diagnostic and therapeutic challenges","volume":"39","author":"Tavares","year":"2017","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1097\/00000478-200110000-00007","article-title":"Progression to Large B-Cell Lymphoma in Splenic Marginal Zone Lymphoma: A Description of a Series of 12 Cases","volume":"25","author":"Camacho","year":"2001","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1093\/annonc\/mdv368","article-title":"Histologic transformation in marginal zone lymphomas","volume":"26","author":"Conconi","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, stag-ing, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1470-2045(03)00981-1","article-title":"Splenic marginal-zone lymphoma: A distinct clinical and pathological entity","volume":"4","author":"Thieblemont","year":"2003","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/aol-20-28","article-title":"Epidemiology of marginal zone lymphoma","volume":"5","author":"Cerhan","year":"2021","journal-title":"Ann. Lymphoma"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/sj.leu.2405068","article-title":"Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria","volume":"22","author":"Matutes","year":"2008","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.2005.06.008","article-title":"Role of Anti-Hepatitis C Virus (HCV) Treatment in HCV-Related, Low-Grade, B-Cell, Non-Hodgkin\u2019s Lymphoma: A Multicenter Italian Experience","volume":"23","author":"Vallisa","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.clml.2014.07.002","article-title":"Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation Guidelines for the Management of Indolent, Nonfollicular B-Cell Lymphoma (Marginal Zone, Lymphoplasmacytic, and Small Lymphocytic Lymphoma)","volume":"15","author":"Tarella","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_10","first-page":"190","article-title":"Treatment of Splenic Marginal Zone Lymphoma With Rituximab Monotherapy: Progress Report and Comparison With Splenectomy","volume":"18","author":"Kalpadakis","year":"2013","journal-title":"Oncology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.3109\/10428194.2013.861067","article-title":"Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment","volume":"55","author":"Lenglet","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/j.seminhematol.2010.01.004","article-title":"Treatment of Splenic Marginal Zone Lymphoma: Splenectomy Versus Rituximab","volume":"47","author":"Bennett","year":"2010","journal-title":"Semin. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.3109\/10428194.2013.845884","article-title":"Treatment of splenic marginal zone lymphoma: Should splenectomy be abandoned?","volume":"55","author":"Kalpadakis","year":"2014","journal-title":"Leuk Lymphoma."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/hon.844","article-title":"Re: Rituximab monotherapy is highly effective in splenic marginal zone lymphoma","volume":"26","author":"Bennett","year":"2008","journal-title":"Hematol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/bjh.12036","article-title":"Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma","volume":"159","author":"Else","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/cncr.21931","article-title":"Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone","volume":"107","author":"Tsimberidou","year":"2006","journal-title":"Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.beha.2016.07.004","article-title":"Treatment of splenic marginal zone lymphoma","volume":"30","author":"Kalpadakis","year":"2016","journal-title":"Best Pr. Res. Clin. Haematol."},{"key":"ref_18","first-page":"856","article-title":"Rituximab monotherapy for splenic marginal zone lymphoma","volume":"90","author":"Bennett","year":"2005","journal-title":"Haematologica"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/bjh.15641","article-title":"Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: Results from the phase II BRISMA\/IELSG36 study","volume":"183","author":"Iannitto","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.semcancer.2013.09.001","article-title":"B-cell receptor signaling as a driver of lymphoma development and evolution","volume":"Volume 23","author":"Niemann","year":"2013","journal-title":"Seminars in Cancer Biology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1182\/bloodadvances.2020003121","article-title":"Durable ibrutinib responses in relapsed\/refractory marginal zone lymphoma: Long-term follow-up and biomarker analysis","volume":"24","author":"Noy","year":"2020","journal-title":"Blood Adv."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3324\/haematol.2011.054080","article-title":"BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas","volume":"97","author":"Yan","year":"2012","journal-title":"Haematologica"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/13543784.2021.1855140","article-title":"Investigational drugs for the treatment of diffuse large B-cell lymphoma","volume":"30","author":"Patriarca","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1200\/JCO.2008.17.7980","article-title":"Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma","volume":"27","author":"Goy","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/bjh.15843","article-title":"Lenalidomide plus rituximab (R2) in previously untreated marginal zone lymphoma: Subgroup analysis and long-term follow-up of an open-label phase 2 trial","volume":"185","author":"Becnel","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7513","DOI":"10.1200\/JCO.2019.37.15_suppl.7513","article-title":"MAGNIFY: Phase IIIb interim analysis of induction R2 followed by maintenance in relapsed\/refractory indolent non-Hodgkin lymphoma","volume":"37","author":"Andorsky","year":"2019","journal-title":"JCO"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): A randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.clml.2019.09.612","article-title":"Treatment of Patients with Relapsed\/Refractory Non-Hodgkin Lymphoma with Venetoclax: A Single-Center Evaluation of Off-Label Use","volume":"19","author":"Hughes","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1182\/blood.V126.23.254.254","article-title":"A phase 1 study of venetoclax (ABT-199\/GDC-0199) monotherapy in patients with relapsed\/refractory non-Hodgkin lymphoma","volume":"126","author":"Gerecitano","year":"2015","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/annonc\/mdy256","article-title":"Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: A phase Ib dose-finding study","volume":"29","author":"Swinnen","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_33","first-page":"2628","article-title":"Venetoclax-rituximab with or without bendamustine vs. bendamustine-rituximab in relapsed\/refractory follicular lymphoma","volume":"136","author":"Zinzani","year":"2020","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1182\/blood-2018-11-880526","article-title":"Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: Results from the CAVALLI phase 1b trial","volume":"133","author":"Zelenetz","year":"2019","journal-title":"Blood"},{"key":"ref_35","first-page":"212574","article-title":"Venetoclax: Evidence to date and clinical potential","volume":"8","author":"Desai","year":"2019","journal-title":"Drugs Context"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"964","DOI":"10.5858\/2010-0741-LER","article-title":"Nodal Marginal Zone Lymphoma with Increased Large Cells: Myth Versus Entity","volume":"135","author":"Kaur","year":"2011","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Aaseb\u00f8, E., Berven, F.S., Hovland, R., D\u00f8skeland, S.O., Bruserud, \u00d8., Selheim, F., and Hernandez-Valladares, M. (2020). The Progression of Acute Myeloid Leukemia from First Diagnosis to Chemoresistant Relapse: A Comparison of Proteomic and Phosphoproteomic Profiles. Cancers, 12.","DOI":"10.3390\/cancers12061466"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12308-012-0166-4","article-title":"FASN and CD36 predict survival in rituximab-treated diffuse large B-cell lymphoma","volume":"6","author":"Danilova","year":"2013","journal-title":"J. Hematop."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/6\/328\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:25:01Z","timestamp":1760138701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/6\/328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,6]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["curroncol29060328"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29060328","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,6]]}}}